FDA Class II Recall: Asteria Health's Testosterone Pellets Contaminated with Metal Particulate
F.H. INVESTMENTS, Inc. (dba Asteria Health) has initiated a Class II recall of 194,336 Testosterone, 200 mg sterile pellets due to potential metal particulate contamination. This event highlights critical quality control challenges in sterile drug manufacturing, necessitating immediate action from procurement and regulatory teams to assess supply chain exposure and identify alternative suppliers for this essential hormone therapy.
FDA Class II Recall: Metal Particulate Contamination in Testosterone Pellets
F.H. INVESTMENTS, Inc., operating as Asteria Health, has initiated a voluntary Class II recall for a significant volume of its Testosterone, 200 mg, 1 Sterile Pellet product. The recall, identified by number D-0324-2026, was prompted by the potential presence of metal particulate matter, classified as a foreign substance, within the sterile pellets. This poses a direct risk of adverse health consequences for patients, leading to the FDA's Class II classification, which indicates that exposure may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. The firm initiated this recall on January 26, 2026, with the FDA classifying it on February 11, 2026. For procurement directors and regulatory affairs heads, this event underscores the critical importance of stringent quality control protocols in the manufacturing of sterile drug products. The presence of foreign particulate matter can compromise patient safety and lead to significant supply chain disruptions, demanding immediate attention to supplier qualification and product integrity checks.
Product Scope and Manufacturing Facility Details
The recall specifically targets 194,336 pellets of Testosterone, 200 mg, 1 Sterile Pellet, distributed nationwide across the USA. This product, bearing NDC: 79559-1200-43, is manufactured by F.H. INVESTMENTS, Inc. (dba Asteria Health) at its facility located at 432 Industrial Ln, Birmingham, AL 35211-4465, United States. The affected lots include: 251000127 (Exp. 06/03/2026), 251000128 (Exp. 06/05/2026), 251000133, 251000134, 251000135 (all Exp. 06/16/2026), 251000138, 251000139, 251000140, 251000141 (all Exp. 06/25/2026), 251000147, 251000148, 251000149 (all Exp. 07/28/2026), 251000156, 251000157 (all Exp. 08/08/2026), 251000164, 251000165, 251000166 (all Exp. 08/22/2026), 251000169 (Exp. 08/29/2026), 251000171, 251000172 (all Exp. 09/03/2026), and 251000180 (Exp. 09/19/2026). For supply chain VPs, understanding these specific lot numbers and expiration dates is crucial for identifying affected inventory and preventing further distribution. The nationwide distribution pattern indicates a broad market impact within the United States, requiring immediate communication with downstream partners and healthcare providers.
Supply Chain Exposure and Market Impact for Testosterone Products
The recall of nearly 200,000 units of Testosterone, 200 mg sterile pellets by Asteria Health creates an immediate supply gap for this specific formulation within the U.S. market. Procurement directors must promptly assess their current inventory, purchase orders, and contracts to determine direct exposure to the affected lots (NDC: 79559-1200-43). This disruption primarily impacts U.S. healthcare providers, pharmacies, and patients who rely on this particular testosterone product for hormone replacement therapy. While the knowledge graph does not provide specific market share data for Asteria Health, a recall of this magnitude for a specialized drug can lead to increased demand for alternative testosterone formulations or products from other manufacturers. Business development executives should monitor market dynamics closely, as this event could present opportunities for competitors with robust quality systems and available capacity to capture market share. The incident underscores the fragility of single-source or limited-source supply chains for critical medications.
Strategic Sourcing: Identifying Alternative Testosterone Suppliers
Given the ongoing Class II recall by F.H. INVESTMENTS, Inc. (dba Asteria Health) for its Testosterone, 200 mg sterile pellets, procurement teams must urgently evaluate alternative sourcing strategies. Our current knowledge graph does not identify specific alternative suppliers for this particular product formulation. This absence necessitates a proactive and rapid identification process for new qualified manufacturers of Testosterone, 200 mg sterile pellets or equivalent hormone therapy products. The qualification of new pharmaceutical suppliers is a complex and time-consuming process, involving comprehensive due diligence, facility audits, and potentially new regulatory submissions to ensure compliance with cGMP standards and product safety. Supply chain VPs should prioritize suppliers with a strong track record of FDA compliance and robust quality management systems. Diversifying the supplier base for critical APIs and finished drug products is essential to mitigate future risks associated with quality deviations or regulatory actions, ensuring continuity of patient care and market supply.
Broader Industry Context: Persistent Contamination Risks in Pharmaceutical Manufacturing
While F.H. INVESTMENTS, Inc. (dba Asteria Health) does not have a prior regulatory history within our knowledge graph, this recall for metal particulate contamination is not an isolated incident in the pharmaceutical industry. Recent parallel events highlight a recurring challenge with foreign particulate matter and sterility assurance. For instance, Guardian Drug Co. Inc. faced nationwide Class II recalls in June 2026 for metallic contamination in both Tums Antacid and Calcium Carbonate Antacids. Additionally, other Class II recalls in the same period, such as Essential Wellness Pharma's Progesterone Injection and Spectra Medical Devices' Lidocaine HCl Injection, were due to sterility assurance deficiencies. These events collectively signal heightened FDA scrutiny on manufacturing quality and the integrity of sterile and oral solid dosage forms. Regulatory affairs heads must recognize this trend as indicative of systemic vulnerabilities across the industry, requiring proactive investment in advanced manufacturing technologies, robust environmental monitoring, and comprehensive quality management systems to prevent similar costly and reputation-damaging recalls.
Remediation Pathways and Future Regulatory Scrutiny for Asteria Health
The Class II recall initiated by F.H. INVESTMENTS, Inc. (dba Asteria Health) remains ongoing, indicating that the firm is actively managing the retrieval of affected product lots from the market. Moving forward, Asteria Health is expected to conduct a thorough root cause investigation into the source of the metal particulate matter, implement comprehensive corrective and preventive actions (CAPA), and demonstrate the effectiveness of these measures to the FDA. This process typically involves detailed process analysis, equipment validation, and enhanced quality control checks. The FDA will closely monitor the recall's progress and the firm's remediation efforts, likely through follow-up inspections. For business development executives and regulatory affairs teams, this means potential extended periods of manufacturing disruption or increased regulatory oversight for Asteria Health. Companies relying on this supplier should prepare contingency plans, including potential inventory build-up from alternative sources, and assess the financial implications of prolonged supply chain instability or increased costs associated with qualifying new suppliers for Testosterone, 200 mg sterile pellets.